Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

The FDA has expanded the label of Ozempic, approving the Novo Nordisk product for reducing the risk of worsening kidney disease and kidney failure as well as reducing the risk of death.

If you’re interested in using Ozempic for weight loss, which is an off-label use, talk with your doctor first. They’ll help determine whether Ozempic is an appropriate weight loss strategy for ...

Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 per cent in 2024 to 100 billion Danish ...

Semaglutide was a top-selling drug in 2023, and its popularity only continues to grow, as it’s been increasingly prescribed off-label for ... price for Ozempic is $997.58 per pen without insurance.

Ozempic has skyrocketed in popularity as both a diabetes medication and a weight loss aid, but a growing number of patients are reporting an unexpected and puzzling side effect. Some users have ...

The list price for a one-month supply of Ozempic costs close to $1,000 without insurance or manufacturer coupons. According to CMS data, Medicare Part D spending on Ozempic was more than $4.6 ...

Rapid fat loss from GLP-1 medications like Ozempic can lead to 'Ozempic face', characterized by hollow cheeks and sagging skin. Drinking water, eating a protein-rich diet, and practicing face yoga ...

Black box warnings for the Ozempic include that it may increase the risk of developing thyroid tumors. The label also warns about the risk of developing stomach paralysis which can lead to nausea ...

Last month, the European Medicines Agency approved Novo's request to add risk reduction for renal disease-related events to the Ozempic label. According to Novo Nordisk, over 40% of persons with ...

You may take Ozempic or another drug to control your diabetes or lose weight, but these so-called GLP-1s also have a host of other effects ‒ some good and some not so good. A new study ...